Last reviewed · How we verify

Synthetic neutralising antibodies — Competitive Intelligence Brief

Synthetic neutralising antibodies (Synthetic neutralising antibodies) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious Diseases.

phase 3 Monoclonal antibody Specific viral proteins (e.g. SARS-CoV-2 spike protein) Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Synthetic neutralising antibodies (Synthetic neutralising antibodies) — University of Oxford. Synthetic neutralising antibodies work by binding to and neutralising specific viral proteins, thereby preventing the virus from infecting cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Synthetic neutralising antibodies TARGET Synthetic neutralising antibodies University of Oxford phase 3 Monoclonal antibody Specific viral proteins (e.g. SARS-CoV-2 spike protein)
[89Zr]Zr-crefmirlimab berdoxam 89zr-zr-crefmirlimab-berdoxam Pfizer marketed Radiolabeled Monoclonal Antibody Fibroblast Activation Protein (FAP) Not specified
Venetoclax; Rituximab venetoclax-rituximab Pfizer marketed BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab) BCL-2 (venetoclax); CD20 (rituximab) N/A
Hympavzi MARSTACIMAB Pfizer Inc marketed Monoclonal Antibody Factor Xa 2025-01-01
Beyfortus NIRSEVIMAB AstraZeneca marketed Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] RSV 2023-01-01
Darzalex daratumumab Johnson & Johnson marketed Monoclonal antibody CD38 2015-01-01
Praxbind IDARUCIZUMAB Boehringer Ingelheim marketed Humanized Monoclonal Antibody Fragment [EPC] dabigatran and its acylglucuronide metabolites 2015-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Synthetic neutralising antibodies — Competitive Intelligence Brief. https://druglandscape.com/ci/synthetic-neutralising-antibodies. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: